Skip to main content

Is Risk-Based Monitoring Just A Fad?

by Marin Richeson on February 25th, 2016 | ~ minute read

pharmaceutical-risk-based-monitoring

AI at Perficient

Revolutionize Your Business With Generative AI

From product design and software development to virtual agents, content creation, and reporting, GenAI is transforming business. Our AI experts help you unlock GenAI’s full potential and drive growth.

Let’s Get Started

While some of you might be hoping that RBM is just a trendy idea that we’ll soon forget, I have to say that when regulatory agencies take the time to draft and produce guidance documents on the topic…

United States Food and Drug Administration (FDA): Guidance for Industry, Oversight of Clinical Investigations – A Risk-Based Approach to Monitoring (August 2013)
European Medicines Agency (EMA): Reflection Paper on Risk Based Quality Management in Clinical Trials (November 2013)

…it’s most likely here to stay.

Tags

biotech clinical trials compliance CRO medical device pharma

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Marin Richeson

Marin joined the life sciences industry in 2001. Over the course of her tenure, she has held roles in clinical finance, IT, quality assurance, and validation. The diversity of her experience provides her with a unique perspective on the interconnectedness of this complex, multi-faceted industry. Marin Richeson is a lead business consultant in Perficient's life sciences practice.

More from this Author